文献速递间质性肺疾病

糖皮质激素治疗纤维化间质性肺疾病急性加重

Steroid therapy in acute exacerbation of fibrotic interstitial lung disease.
PubMed 文献 · Respirology · 2024-06-02

这项两中心回顾性观察研究纳入107例纤维化间质性肺疾病急性加重(AE-FILD)患者,其中46例(43%)在入院72小时内接受糖皮质激素治疗。结果显示,激素使用与住院死亡或需肺移植风险升高相关(OR 4.11;95%CI 1.00-16.83;p=0.049),全因死亡风险亦升高(HR 3.25;95%CI 1.56-6.77;p<0.01),提示临床上应审慎使用激素。

要点

  • AE-FILD住院死亡风险高,程度与AE-IPF相似
  • 激素治疗与住院死亡或肺移植风险升高相关(OR 4.11)
  • 激素组中位生存221天,短于非激素组520.5天

核心结论

  • AE-FILD患者死亡风险高,程度与AE-IPF相似,即使接受激素治疗亦然。
  • 研究者建议临床医生考虑其他诱发加重因素并审慎使用激素,尚需前瞻性试验明确激素在AE-FILD中的作用。

研究设计与样本

  • 两中心回顾性观察研究,以编码算法筛选10年间AE-FILD病例并逐一评估。
  • 共纳入107例AE-FILD患者,含IPF与非IPF ILD,其中46例(43%)接受急性激素治疗。
  • 激素治疗定义为入院72小时内使用泼尼松龙等效剂量≥0.5 mg/kg/天且≥3天。
  • 采用二元logistic回归分析激素治疗与住院死亡或需肺移植的关系。

主要发现

  • 激素组较年轻、合并症较少,但氧需求更高;入院前FVC、DLCO、诊断分布与吸烟史相似。
  • 激素平均治疗剂量为4.59 mg/kg/天。
  • 激素使用与住院死亡或移植风险升高相关(OR 4.11;95%CI 1.00-16.83;p=0.049)。
  • 非IPF患者中激素组全因死亡风险低于IPF患者(HR 0.21;95%CI 0.04-0.96;p=0.04)。
  • 激素组中位生存期缩短(221 vs. 520.5天),全因死亡风险升高(HR 3.25;95%CI 1.56-6.77;p<0.01)。

关键数值与推荐

  • 激素治疗定义:入院72小时内泼尼松龙等效剂量≥0.5 mg/kg/天,持续≥3天。
  • 激素平均剂量4.59 mg/kg/天。
  • 主要结局:住院死亡或需肺移植,OR 4.11(95%CI 1.00-16.83;p=0.049)。
  • 全因死亡:HR 3.25(95%CI 1.56-6.77;p<0.01);中位生存221 vs. 520.5天。
  • 非IPF患者全因死亡HR 0.21(95%CI 0.04-0.96;p=0.04)。

临床怎么用

  • AE-FILD患者即使使用激素,死亡风险仍高,应积极寻找并处理其他诱发加重因素。
  • 激素使用需权衡利弊、审慎决策,尤其应关注住院死亡与移植风险。
  • 非IPF的纤维化ILD患者使用激素的获益与风险可能与IPF不同,需个体化评估。

局限性

  • 回顾性观察设计,激素组与对照组基线不完全可比(激素组更年轻、合并症更少但氧需求更高)。
  • 样本量较小(共107例,激素组46例),部分结果置信区间较宽。
  • 激素治疗为观察性暴露而非随机分配,可能存在适应证混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Evidence for the benefit of steroid therapy in acute exacerbations (AEs) of idiopathic pulmonary fibrosis (IPF) is limited; however, they remain a cornerstone of management in other fibrotic interstitial lung diseases. This retrospective observational study assesses the effect of steroid treatment on in-hospital mortality in patients with acute exacerbation of fibrotic interstitial lung disease (AE-FILD) including IPF and non-IPF ILDs. METHODS: AE-FILD cases over a 10-year period were filtered using a code-based algorithm followed by individual case evaluation. Binary logistic regression analysis was used to assess the relationship between corticosteroid treatment (defined as ≥0.5 mg/kg/day of prednisolone-equivalent for ≥3 days within the first 72 h of admission) and in-hospital mortality or need for lung transplantation. Secondary outcomes included readmission, overall survival, requirement for domiciliary oxygen and rehabilitation. RESULTS: Across two centres a total of 107 AE-FILD subjects were included, of which 46 patients (43%) received acute steroid treatment. The steroid cohort was of younger age with fewer comorbidities but had higher oxygen requirements. Pre-admission FVC and DLCO, distribution of diagnoses and smoking history were similar. The mean steroid treatment dose was 4.59 mg/kg/day. Steroid use appeared to be associated with increased risk of inpatient mortality or transplantation (OR 4.11; 95% CI 1.00-16.83; p = 0.049). In the steroid group, there appeared to be a reduced risk of all-cause mortality in non-IPF patients (HR 0.21; 95% CI 0.04-0.96; p = 0.04) compared to their IPF counterparts. Median survival was reduced in the steroid group (221 vs. 520.5 days) with increased risk of all-cause mortality (HR 3.25; 95% CI 1.56-6.77; p < 0.01). CONCLUSION: In this two-centre retrospective study of 107 patients, AE-FILD demonstrates a high risk of mortality, at a level similar to that seen for AE-IPF, despite steroid treatment. Clinicians should consider other precipitating factors for exacerbations and use steroids judiciously. Further prospective trials are needed to determine the role of corticosteroids in AE-FILD.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Koshy K, Barnes H, Farrand E, et al. Steroid therapy in acute exacerbation of fibrotic interstitial lung disease. Respirology. 2024. PMID: 38825348. doi:10.1111/resp.14763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。